clinical endpoint comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-12-14. Numbers and descriptions here follow the published literature rather than marketing material.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
| Property | Value | Notes |
|---|---|---|
| First described | 1977 | Reported as a component of thymosin fraction 5 |
| Sequence length | 28 amino acids | N-terminal residue is acetylated |
| Net charge at neutral pH | Negative | Reflects a high proportion of acidic residues |
| Principal studied uses | Chronic hepatitis B and vaccine adjuvant | Research uses outnumber approved indications |
| Regulatory status | Approved in a limited number of countries | Not approved in the United States or most of Europe |
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
=== Detection in body fluids === Buprenorphine and norbuprenorphine may be quantified in blood or urine to monitor use or non-medical recreational use, confirm a diagnosis of poisoning, or assist in a medicolegal investigation. A significant overlap of drug concentrations exists in body fluids within the possible spectrum of physiological reactions ranging from asymptomatic to comatose. Therefore, knowing both the route of administration of the drug and the level of tolerance to opioids of the individual is critical when results are interpreted.
== External links == Clinical trial number NCT02782741 for "Study to Compare the Efficacy and Safety of Enzyme Replacement Therapies Avalglucosidase Alfa and Alglucosidase Alfa Administered Every Other Week in Patients With Late-onset Pompe Disease Who Have Not Been Previously Treated for Pompe Disease (COMET)" at ClinicalTrials.gov Clinical trial number NCT01898364 for "Safety and Efficacy Evaluation of Repeat neoGAA Dosing in Late Onset Pompe Disease Patients" at ClinicalTrials.gov Clinical trial number NCT02032524 for "Avalglucosidase Alfa Extension Study (NEO-EXT)" at ClinicalTrials.gov Clinical trial number NCT03019406 for "A Study to Assess Safety and Efficacy of Avalglucosidase Alfa Administered Every Other Week in Pediatric Patients With Infantile-onset Pompe Disease Previously Treated With Alglucosidase Alfa (Mini-COMET)" at ClinicalTrials.gov
Legion of Merit (officer grade) at the specific request of "Wild Bill" Donovan, founder of the OSS. Known as the teacher of close combat fighting in Camp X and teaching defendu, a special forces close combat system. Following his instruction at Camp X, Fairbairn was rejoined by his pupil Col. Applegate to form the United States "School for Spies and Assassins", then called "Camp B", now known as Camp David. Not well known by the public because his techniques were often brutal, and were considered too dangerous to be widely publicly known. Some people considered him as a British agent in disguise and a prototype of Ian Fleming's character of James Bond. Fairbairn was also the teacher of Lt. Colonel Robert T. Frederick, the designer of Army Special Unit knife V-42 stiletto which was based on Fairbairn–Sykes commando knife. Fairbairn also a friend of Captain Dermot Michael "Pat" O'Neill, the First Special Service Force's close-combat instructor. In 1945, Colonel Movlid Visaitov, commander of the 255th Separate Chechen-Ingush Cavalry Regiment and the 28th Guards Regiment. Visaitov was the first Soviet officer to shake hands with General Bolling at the Elbe River. On 27 September 1945, General Alois Liška of the Czechoslovak Army under former U.S. command, was awarded by General Ernest N. Harmon in Prague Group Captain Harry Day, Senior Officer at numerous POW camps during World War II, and significantly helped American POWs endure the captivity, as well as organizing escape operations. He received the award on July 5, 1946.
Sources: en.wikipedia.org
== Facilities == Lineage is headquartered in Novi, Michigan, with additional offices around the world. It operates about 223 facilities in North America, including in 37 U.S. states, and warehouses in Australia, Belgium, Canada, China, Denmark, France, Germany, Italy, the Netherlands, New Zealand, Norway, Peru, Poland, Singapore, Spain, Sri Lanka, the United Kingdom, and Vietnam.
== Drying defects == Drying defects are the most common form of degrade in timber, next to natural problems such as knots. There are two types of drying defects, although some defects involve both causes:
== Visibility to humans == The lens of the human eye and surgically implanted lenses block most radiation in the near UV wavelength range of 300–400 nm; shorter wavelengths are blocked by the cornea. Humans also lack color receptor adaptations for ultraviolet rays. However, the photoreceptors of the human retina are quite sensitive to UVA photons but the lens does not focus this light properly, causing UVA light bulbs to look fuzzy. People lacking a lens (a condition known as aphakia) perceive UVA as whitish-blue or whitish-violet. Near-UV radiation is visible to insects, some mammals, and some birds. Birds have a fourth color receptor for ultraviolet rays; this, coupled with eye structures that transmit more UV gives smaller birds "true" UV vision.
Sources: en.wikipedia.org
== Habitat and ecology == Rhizopus oryzae can be found in various soils across the world. For example, it has been found in India, Pakistan, New Guinea, Taiwan, Central America, Peru, Argentina, Namibia, South Africa, Iraq, Somalia, Egypt, Libya, Tunisia, Israel, Turkey, Spain, Italy, Hungary, Czech Republic, Slovakia, Germany, Ukraine, British Isles, and the USA. The soils where R. oryzae has been isolated are varied ranging from grassland, cultivated soils under lupin, corn, wheat, groundnuts, other legumes, sugar canes, rice, citrus plantations, steppe type vegetation, alkaline soils, salt-marshes, farm manure soils, to sewage filled soils. The pH of the soils where the species has been isolated typically range from 6.3 to 7.2. Rhizopus oryzae is often identified as R. arrhizus when isolated from foods. It is found in rotting fruits and vegetables where it is often called R. stolonifer. Unlike the other species such as R. stolonifer, R. oryzae is common in tropical conditions. In East Asia, it is common in peanuts. For instance, there was 21% isolation from peanut kernels from Indonesia. It is present in maize, beans, sorghum, and cowpeas, pecans, hazelnuts, pistachios, wheat, barley, potatoes, sapodillas, and various other tropical foods. Maize meal on which isolates of R. oryzae had been grown was found to be toxic to ducklings and rats, causing growth depression.
The skates (Rajidae, Arhynchobatidae, Anacanthobatidae) are the only rays that are oviparous. Females lay egg cases onto the sea floor after fertilization occurs in utero. While in utero, a protected case forms around the embryo which is called the egg case. Studies have been done where egg cases were removed from gravid females to ensure proper identification in regard to skate species. Egg cases have distinguishable characteristic traits that are unique to that species, thus making it a great tool for identifying a skate. The two most distinguishable features on the egg case are the keel and the absence or presence of a fibrous covering. A keel runs laterally along both sides of the outer edge of the egg case; it is a flexible structure. Keels will also run the length of the horns on some skate species. Some egg cases have broad keels (greater than 10% of the maximum egg case width) while others have narrow keels (less than 10% of the maximum egg case width). Many egg cases are covered with a layer of fiber; some will have a fine layer while others have a thick layer.
The hybrid layer is hydrophobic, acid resistant and tough. The quality of hybrid layer formed decides the strength of resin dentin interface. When the hybrid layer becomes thicker and more uniform, the bond strength is better.
=== 1999–2005: Film debut and breakthrough === In 1999, Larter made her film debut in the coming-of-age dramedy Varsity Blues, which reunited her with Dawson's Creek star James Van Der Beek and close friend Amy Smart. Smart had persuaded Larter to audition for the movie, in which Larter played Darcy Sears, a love interest for Lance Harbor (Paul Walker). Varsity Blues drew a domestic box office gross of $53 million. Also in 1999, she made supporting appearances in the teen comedies Giving It Up and Drive Me Crazy, and starred in the remake House on Haunted Hill which was made for around $20 million. The horror film about a group of strangers invited to a party at an abandoned asylum, was panned by critics, but grossed $15 million on its opening weekend eventually earning over $40 million overall. Larter starred as Clear Rivers, one of the main characters in the teen supernatural horror film Final Destination (2000). Also starring Devon Sawa from British Columbia, and Kerr Smith, the movie's premise is several teenagers survive a plane crash but are stalked and killed by death itself. Final Destination made $112 million by the end of its theatrical run. In 2001, she appeared in the comedy Legally Blonde with Reese Witherspoon. Larter played Brooke Taylor Windham, a widow accused of her husband Hayworth's murder. The film held the top spot with $20 million in its opening weekend and ended up grossing $141 million worldwide. With $96 million of its total gross deriving from domestic markets, Legally Blonde is her highest-grossing film domestically.
Sources: en.wikipedia.org
Trials differ in patient population, dose schedule, background treatment, and the endpoints used to judge success. Many are small and single-center, so random variation can dominate the reported effects.
Authorization is limited to a small number of countries and covers specific indications such as chronic hepatitis B and vaccine adjuvant use. Availability and labelling differ by jurisdiction.
Most reviews describe it as an immunomodulatory agent with an uncertain clinical effect. They generally call for larger, better-controlled trials before firm conclusions are drawn.
It corresponds to a fragment of the larger protein prothymosin alpha, which is present in many tissues. The isolated 28-amino-acid peptide was originally obtained from thymus preparations, and the pharmaceutical product is synthesized rather than extracted. The term therefore describes both a natural fragment and a manufactured drug substance.